Limited Functionality Warning

We are currently updating our network. During this time, certain functionality may be unavailable, including online orders. We apologize for any inconvenience this may cause you.

Please contact Customer Service with any questions or comments.
Phone: (608) 274-4330
Toll-Free Phone: (800) 356-9526
Email: custserv@promega.com
Hours: 7am – 6pm, CST, Monday-Friday

Citations Search

Sort By:

Biomed. Pharmacother. 104, 383–9. RNA binding protein Lin28B confers gastric cancer cells stemness via directly binding to NRP-1. 2018

Wang, X., Hu, H. and Liu, H.

Notes: This work showed that Lin28B expression is significantly increased in gastric cancer cells and is inversely correlated with patient survival. Regions of the Lin28B mRNA including the 5´ UTR, CDS and 3´ UTR were cloned into a luciferase vector, and expression was monitored using the ONE-Glo™ + Tox Luciferase Reporter and Cell Viability Assay. Reporter assay was normalized to β-galactosidase activity using the VivoGlo™ Luciferin-β-Galactosidase Substrate. Results show Lin28B binds in the 3´UTR of NRP-1 mRNA and activates the downstream Wnt/β-catenin pathway. (5138)

Expand Full Notes »

Bioorg. Med. Chem. Lett. 27, 3177–84. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer. 2017

McGee, T.D. Jr., Yi, H.A., Allen, W.J., Jacobs, A. and Rizzo, R.C.

Notes: HIVgp41 is critical HIV and host cell membrane fusion and viral entry making it an attractive therapeutic target. Here, modified compounds from an original large-scale computational docking screen were assessed for inhibition of viral entry. Cell viability and cell-cell fusion levels were measured using the ONE-Glo™ + Tox Luciferase Reporter and Cell Viability Assay. A single compound showed promising results in both dose-response assays and in silico docking analysis. (5139)

Expand Full Notes »